1. Generics Bulletin
  2. >>Products

Adalvo Puts GLP-2 Agonist Teduglutide In The Crosshairs With ‘Day-1’ Filing

Marketed As Revestive, Treatment For Short Bowel Syndrome Backed By NICE

 
• By Dean Rudge

Adalvo will look to add to its growing portfolio in Europe, expanding in rare disease treatments, after filing for a generic version of Takeda’s Revestive (teduglutide) on ‘day-1’ following the expiry of data exclusivity.

European Health Data Space
• Source: Shutterstock

Adalvo is targeting a first-to-market opportunity, underscoring what it says is its commitment to addressing unmet medical needs in the rare disease segment, after submitting a filing in Europe via the decentralized procedure route for a generic version of Takeda’s Revestive (teduglutide) on ‘day-1’ following the expiry of data exclusivity.

Teduglutide is a glucagon-like peptide-2 (GLP-2) analog, presented as a powder and solvent for solution for injection, that treats adults and children aged four months and above with short bowel syndrome (SBS) – a rare condition that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

More from Products